Pharmaceuticals

Telomir Pharma Stock Soars 35% on Epigenetic Therapy Breakthrough

Telomir Pharmaceuticals surged after new data showed its lead drug could reset disease drivers, sparking investor buzz in a high-risk biotech play.

Medtronic Board Changes and EPS Guidance Update

Medtronic raised its 2026 profit forecast as strong demand offsets tariff risks. See what this means for investors in healthcare device stocks.

Indivior Stock (INDV): Strong Earnings Boost Investor Confidence

Indivior exceeded Q2 2025 expectations, raising full-year forecasts, driven by strong Sublocade demand, boosting stock by ~21%.

CVS Health Stock (CVS): Strong Q2 Performance and Future Outlook

CVS Health showed strong Q2 2025 results, boosting EPS guidance and share price, driven by Aetna and pharmacy growth.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

Exact Sciences Stock (EXAS): Cologuard Plus Expansion Benefits

Exact Sciences broadens partnership with Humana, offering Cologuard Plus for 5.8 million members, enhancing access and driving growth.

ProKidney Stock (PROK): Is the Hype Justified?

ProKidney's stock soared after promising Phase 2 trial results, highlighting the potential but also the risks in biotech investments.

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development

Recursion Pharmaceuticals partners with MIT for Boltz-2, an AI model predicting binding affinity at unprecedented speed and accuracy.

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus

Taysha Gene Therapies (NASDAQ: TSHA) is gaining investor attention with TSHA-102, its lead Rett syndrome gene therapy. Learn why this biotech stock is a rising contender in the CNS space.

Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals

Cidara Therapeutics aims to innovate antivirals with CD388, targeting flu prevention. Positive trial results may boost stock.

Vigil Neuroscience Stock (VIGL): Buyout Boosts Valuation

Vigil Neuroscience's stock soared after Sanofi agreed to buy it for $8.00 per share, tied to the potential success of its Alzheimer’s drug VG-3927.

Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy

Capricor Therapeutics (CAPR) stock climbs as FDA decision nears for its Duchenne therapy, with peak sales forecast at $3.3B by 2038.

Geron Corp Stock (GERN): Demand Recovery on the Rise

Geron Corporation's stock (GERN) is gaining attention due to its promising biotech advancements, particularly with its lead drug, Rytelo.

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials

CytomX Therapeutics stock surges 280% on promising cancer data and a $93.4 million stock offering, bolstering its financial future.

Iovance Biotherapeutics Stock (IOVA): Navigating Turbulent Times

Iovance shares plunged on weak Q1 results and production issues, then bounced 10% as investors reassessed. Legal risks and volatility remain high.